Since established in 1988, AIDS Research Center (ARC) has been
working on HIV- and other retroviruses-related diseases. The principal
objective of ARC is to contribute to the control of HIV infection.
>> To the ARC introduction movie（Mac-only）
Review article written by Dr. Yoshimura (Chief, Division 1) was selected to JIC Most cited article of 2017.
Kazuhisa Yoshimura. Current status of HIV/AIDS in the ART era. Journal of Infection and Chemotherapy, 23:12-16, 2017.
>> JIC Most cited article of 2015, 2016 and 2017
>> Article Page (Open Access)
GHIT has announced to award an investment to a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID.
This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection.
>> GHIT press room >> GHIT web site >> VLP Therapeutics web site
The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations including England and Rwanda.
The SeV vector AIDS vaccine system has been developed by our research group.
>> Press release from IAVI on April 1, 2013
>> Information on this project in IAVI Web
updated on June 16, 2017